The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Open accessAbstract
Regional CAR T cell delivery provides superior protection compared to systemic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 2×
“The rapid acquisition of a CD62L− phenotype may account for their efficient subsequent trafficking to metastatic sites (29).”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Self-citationInducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationSystemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationFedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Self-citationZamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Robinson, B. W., Musk, A. W., & Lake, R. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67025-0 · Cited by 664
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Argani, P., Iacobuzio–Donahue, C. A., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E. M., Yeo, C. J., et al. (2001) · PubMed · Cited by 574
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Self-citationZhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Self-citationDiscovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Hassan, R., Laszik, Z. G., Lerner, M., Raffeld, M., Postier, R., & Brackett, D. (2005) · American Journal of Clinical Pathology · doi:10.1309/f1b6-4cl7-h8vj-keaf · Cited by 236
Hassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A., Kreitman, R. J., Miettinen, M. M., Steinberg, S. M., Fowler, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006941 · Cited by 234
Zhao, Y., Bennett, A. D., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L. Y. L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 220
Rabinovich, B. A., Ye, Y., Etto, T., Chen, J. Q., Levitsky, H. I., Overwijk, W. W., Cooper, L. J. N., Gelovani, J., & Hwu, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804105105 · Cited by 208
Servais, E. L., Colovos, C., Rodriguez, L., Bograd, A. J., Nitadori, J.-I., Sima, C., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2614 · Cited by 202
Self-citationHassan, R., Cohen, S. J., Phillips, M., Pastan, I., Sharon, E., Kelly, R. J., Schweizer, C., Weil, S., & Laheru, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2275 · Cited by 201
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187
Kachala, S. S., Bograd, A. J., Villena-Vargas, J., Suzuki, K., Servais, E. L., Kadota, K., Chou, J., Sima, C. S., Vertes, E., Rusch, V. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1862 · Cited by 185
Self-citationHassan, R., Kindler, H. L., Jahan, T., Bazhenova, L., Reck, M., Thomas, A., Pastan, I., Parno, J., O'Shannessy, D. J., Fatato, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0804 · Cited by 180
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Tchou, J., Wang, L.-C., Selven, B., Zhang, H., Conejo-Garcia, J., Borghaei, H., Kalos, M., Vondeheide, R. H., Albelda, S. M., June, C. H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2018-4 · Cited by 172
Frierson, H. F., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H., & Hampton, G. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00177-1 · Cited by 171
Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cells
Jensen, M. C., & Riddell, S. R. (2013) · Immunological Reviews · doi:10.1111/imr.12139 · Cited by 170
Yamada, N., Oizumi, S., Kikuchi, E., Shinagawa, N., Konishi-Sakakibara, J., Ishimine, A., Aoe, K., Gemba, K., Kishimoto, T., Torigoe, T., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0881-6 · Cited by 169
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 157
Stone, J. D., Aggen, D. H., Schietinger, A., Schreiber, H. W., & Kranz, D. M. (2012) · OncoImmunology · doi:10.4161/onci.20592 · Cited by 118
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Gade, T. P. F., Hassen, W., Santos, E. B., Gunset, G., Saudemont, A., Gong, M., Brentjens, R. J., Zhong, X.-S., Stephan, M. T., Stefanski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0436 · Cited by 117
Self-citationvan Herpen, C. M. L., van der Laak, J. A. W. M., de Vries, I. J. M., van Krieken, J. H., de Wilde, P. C., Balvers, M. G. J., Adema, G. J., & Mulder, P. H. M. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1524 · Cited by 104
Thom, A. K., Alexander, H. R., Andrich, M. P., Barker, W. C., Rosenberg, S. A., & Fraker, D. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.264 · Cited by 103
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
Einama, T., Homma, S., Kamachi, H., Kawamata, F., Takahashi, K., Takahashi, N., Taniguchi, M., Kamiyama, T., Furukawa, H., Matsuno, Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.235 · Cited by 88
Suzuki, K., Kadota, K., Sima, C. S., Sadelain, M., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1073-8 · Cited by 77
Self-citationGENE THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA
Sterman, D. H., Kaiser, L. R., & Albelda, S. Μ. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70008-3 · Cited by 72
Adusumilli, P. S., Stiles, B. M., Chan, M., Mullerad, M., Eisenberg, D. P., Ben‐Porat, L., Huq, R., Rusch, V. W., & Fong, Y. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.877 · Cited by 63
Self-citationFeng, Y., Xiao, X., Zhu, Z., Streaker, E. D., Ho, M., Pastan, I. H., & Dimitrov, D. S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0945 · Cited by 62
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Kawamata, F., Kamachi, H., Einama, T., Homma, S., Tahara, M., MIYAZAKI, M., Tanaka, S., Kamiyama, T., Nishihara, H., Taketomi, A., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1662 · Cited by 61
Engels, B., Chervin, A. S., Sant, A. J., Kranz, D. M., & Schreiber, H. W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.286 · Cited by 55
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Bograd, A. J., Suzuki, K., Vertes, E. L., Colovos, C., Morales, E. A., Sadelain, M., & Adusumilli, P. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1103-6 · Cited by 55
Self-citationRizk, N. P., Servais, E. L., Tang, L. H., Sima, C. S., Gerdes, H., Fleisher, M., Rusch, V. W., & Adusumilli, P. S. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0993 · Cited by 40
Self-citationNovel Approaches to Enhance the Specificity and Safety of Engineered T Cells
Fedorov, V. D., Sadelain, M., & Kloss, C. C. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000040 · Cited by 35
Self-citationAn In Vivo Platform for Tumor Biomarker Assessment
Servais, E. L., Suzuki, K., Colovos, C., Rodriguez, L., Sima, C. S., Fleisher, M., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026722 · Cited by 22
Self-citationMesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Villena‐Vargas, J., & Adusumilli, P. S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.03 · Cited by 16
Self-citationTranslational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma
Adusumilli, P. S. (2014) · Cancer · doi:10.1002/cncr.28883 · Cited by 4
Self-citation
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Self-citationTGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Metadata
- Authors
- Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M.
- Venue
- Science Translational Medicine
- Published
- 2014-11-05
- Volume
- 6
- Issue
- 261
- Pages
- 261ra151-261ra151
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2169876627
- Cited by
- 572
- References
- 56
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.